ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Petr Novak*, Branislav Kovacech, Stanislav Katina, Reinhold Schmidt, Philip Scheltens, Eva Kontsekova, Stefan Ropele, Lubica Fialova, Milica Kramberger, Natalia Paulenka-Ivanovova, Miroslav Smisek, Jozef Hanes, Eva Stevens, Andrej Kovac, Stanislav Sutovsky, Vojtech Parrak, Peter Koson, Michal Prcina, Jaroslav Galba, Martin CenteTomas Hromadka, Peter Filipcik, Juraj Piestansky, Maria Samcova, Carmen Prenn-Gologranc, Roman Sivak, Lutz Froelich, Michal Fresser, Martin Rakusa, John Harrison, Jakub Hort, Markus Otto, Duygu Tosun, Matej Ondrus, Bengt Winblad, Michal Novak, Norbert Zilka

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Alzheimer’s disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of AADvac1, an active peptide vaccine designed to target pathological tau in AD (EudraCT 2015-000630-30). Eleven doses of AADvac1 were administered to patients with mild AD dementia at 40 μg per dose over the course of the trial. The primary objective was to evaluate the safety and tolerability of long-term AADvac1 treatment. The secondary objectives were to evaluate immunogenicity and efficacy of AADvac1 treatment in slowing cognitive and functional decline. A total of 196 patients were randomized 3:2 between AADvac1 and placebo. AADvac1 was safe and well tolerated (AADvac1 n = 117, placebo n = 79; serious adverse events observed in 17.1% of AADvac1-treated individuals and 24.1% of placebo-treated individuals; adverse events observed in 84.6% of AADvac1-treated individuals and 81.0% of placebo-treated individuals). The vaccine induced high levels of IgG antibodies. No significant effects were found in cognitive and functional tests on the whole study sample (Clinical Dementia Rating-Sum of the Boxes scale adjusted mean point difference −0.360 (95% CI −1.306, 0.589)), custom cognitive battery adjusted mean z-score difference of 0.0008 (95% CI −0.169, 0.172). We also present results from exploratory and post hoc analyses looking at relevant biomarkers and clinical outcomes in specific subgroups. Our results show that AADvac1 is safe and immunogenic, but larger stratified studies are needed to better evaluate its potential clinical efficacy and impact on disease biomarkers.
Original languageEnglish
Pages (from-to)521-534
JournalNature Aging
Issue number6
Publication statusPublished - 1 Jun 2021

Cite this